Survival parameters of transplant-ineligible patients treated with the alternation of R-CHOP and R-cytarabine. (A) PFS and overall survival (OS) of 67 patients treated with the alternation of R-CHOP and R-cytarabine (2 g/m², 2 doses at 24 hours), 3+3 cycles, and maintenance rituximab (every 3 months for 2 years, for a total of 8 doses). (B) PFS according to MIPI. (C) OS according to MIPI. MIPI, Mantle Cell Lymphoma International Prognostic Index; MIPI-L, MIPI-low risk; MIPI-I, MIPI-intermediate risk; MIPI-H, MIPI-high risk; nr, not reached; PFS, progression-free survival.